10 lessons for using social media from a former FDA official

03/27/2013 | PharmaLive.com

Pharma companies are wary about how they communicate with patients through social media, but the FDA's 2011 draft guidance, "Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices," offers some valuable insight, writes Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA. Pitts advises companies to remember that the message is what is important to the FDA, not the medium, and he offers 10 insights into the agency's draft guidance.

View Full Article in:

PharmaLive.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT